Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 841.00K | 898.30K | 964.50K | 1.08M | 891.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 841.00K | 898.30K | 964.50K | 1.08M | 891.40K |
| Cost of Revenue | 559.80K | 563.10K | 597.40K | 650.70K | 506.10K |
| Gross Profit | 281.30K | 335.30K | 367.10K | 424.40K | 385.20K |
| SG&A Expenses | 674.20K | 652.20K | 609.20K | 617.10K | 492.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.24M | 1.22M | 1.22M | 1.29M | 1.14M |
| Operating Income | -402.70K | -326.40K | -251.80K | -216.60K | -247.70K |
| Income Before Tax | -533.30K | -452.20K | -358.30K | -263.40K | -291.90K |
| Income Tax Expenses | 1.20K | 1.20K | 1.20K | 1.20K | -- |
| Earnings from Continuing Operations | -0.53 | -0.45 | -0.36 | -0.26 | -0.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -534.50K | -453.40K | -359.50K | -264.60K | -291.90K |
| EBIT | -402.70K | -326.40K | -251.80K | -216.60K | -247.70K |
| EBITDA | -348.20K | -271.50K | -196.70K | -162.20K | -207.40K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Average Diluted Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |